日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody-drug conjugate.

ozuriftamab vedotin (BA3021) 是一种新型 ROR2 特异性条件活性生物抗体药物偶联物,其临床前开发

Chang Hwai Wen, Frey Gerhard, Wang Jing, Liu Haizhen, Xing Charles, Chen Jian, Boyle William J, Short Jay M

Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody-drug conjugate.

mecbotamab vedotin (BA3011) 是一种新型的 AXL 特异性条件活性生物抗体药物偶联物,其临床前开发

Chang Hwai Wen, Wang Jing, Liu Haizhen, Xing Charles, Chen Jian, Frey Gerhard, Boyle William J, Short Jay M

A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy

一种新型条件性活性生物制剂抗EpCAM x 抗CD3双特异性抗体,具有协同肿瘤选择性,可用于癌症免疫治疗。

Frey, Gerhard; Cugnetti, Ana Paula G; Liu, Haizhen; Xing, Charles; Wheeler, Christina; Chang, Hwai Wen; Boyle, William J; Short, Jay M

Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches

通过蛋白质相关化学开关生成肿瘤选择性条件活性生物制剂抗CTLA4抗体

Chang, Hwai Wen; Frey, Gerhard; Liu, Haizhen; Xing, Charles; Steinman, Lawrence; Boyle, William J; Short, Jay M

The Use of Somatic Hypermutation for the Affinity Maturation of Therapeutic Antibodies

利用体细胞高频突变进行治疗性抗体的亲和力成熟

Bowers, Peter M; Boyle, William J; Damoiseaux, Robert

Role of RANK ligand in mediating increased bone resorption in early postmenopausal women

RANK配体在介导早期绝经后妇女骨吸收增加中的作用

Eghbali-Fatourechi, Guitty; Khosla, Sundeep; Sanyal, Arunik; Boyle, William J; Lacey, David L; Riggs, B Lawrence